This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue

      

Leaving GSK Pro

You are leaving GSK Pro to visit a separate website not associated with GSK Pro, a portal for US Healthcare Professionals.There are website links to third-party sites on GSK Pro. GSK is not responsible for content on third-party websites.

Continue

Cancel

Nurse Patient Image

HAVING THE COVID-19 VACCINATION CONVERSATION?

Use the opportunity to mention meningitis B (MenB). Are you prepared for the discussion?

Indication

BEXSERO is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. BEXSERO is approved for use in individuals aged 10 through 25 years.

Approval of BEXSERO is based on demonstration of immune response, as measured by serum bactericidal activity against three serogroup B strains representative of prevalent strains in the United States. The effectiveness of BEXSERO against diverse serogroup B strains has not been confirmed.

People Image

Reserve Your Spot

Attend webinars to learn more about MenB.

> Register Now

IMAGE - Computer

Reserve Your Spot

Attend webinars to learn more about MenB.

> Register Now

Monitor Image

Place an Order Today

Stock up on BEXSERO with GSKDirect.

> Order Now

Headset - Image

GSK is here to Help

Speak with a GSK representative, chatbot, or medical expert for assistance.

> Contact Us

Pointer - Image

Get the Latest Product Updates

Register now for your free account.

> Sign Up Now

Vaccination may not protect all recipients.

DON’T DISREGARD THE THREAT OF MenB

Although meningococcal disease is uncommon, it can progress quickly. In fact, it can lead to death.3

> GET THE FACTS

EXPLORE CLINICAL DATA

BEXSERO demonstrated serum bactericidal activity against 3 strains selected to measure responses to 3 respective vaccine antigens prevalent among strains in the US.1,*

*Immune response data were recorded for antigens fHbp, NadA, and PorA P1.4. However, a suitable strain for assessing immune response was not available for NHBA-specific antibodies.1

> SEE THE DATA

References

  1. Prescribing Information for BEXSERO.
  2. Prescribing Information for Trumenba.
  3. Pelton SI. Meningococcal disease awareness: clinical and epidemiological factors affecting prevention and management in adolescents. J Adolesc Health. 2010;46:S9-S15.

Indication

BEXSERO is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. BEXSERO is approved for use in individuals aged 10 through 25 years.

Approval of BEXSERO is based on demonstration of immune response, as measured by serum bactericidal activity against three serogroup B strains representative of prevalent strains in the United States. The effectiveness of BEXSERO against diverse serogroup B strains has not been confirmed.

Important Safety Information for BEXSERO

  • BEXSERO is contraindicated in cases of hypersensitivity, including severe allergic reaction, to any component of the vaccine, or after a previous dose of BEXSERO
  • Appropriate observation and medical treatment should always be readily available in case of an anaphylactic reaction following the administration of the vaccine
  • The tip caps of the prefilled syringes contain natural rubber latex, which may cause allergic reactions
  • Syncope (fainting) can occur in association with administration of BEXSERO. Ensure procedures are in place to avoid injury from falling associated with syncope
  • The most common solicited adverse reactions observed in clinical trials were pain at the injection site (≥83%), myalgia (≥48%), erythema (≥45%), fatigue (≥35%), headache (≥33%), induration (≥28%), nausea (≥18%), and arthralgia (≥13%)
  • Vaccination with BEXSERO may not provide protection against all meningococcal serogroup B strains
  • Some individuals with altered immunocompetence may have reduced immune responses to BEXSERO
  • Individuals with certain complement deficiencies and individuals receiving treatment that inhibits terminal complement activation (for example, eculizumab) are at increased risk for invasive disease caused by Neisseria meningitidis serogroup B even if they develop antibodies following vaccination with BEXSERO
  • Vaccination with BEXSERO may not result in protection in all vaccine recipients



Please see full Prescribing Information for BEXSERO.

Trademarks are property of their respective owners.